Latest Capital Markets News

Sayona Mining has completed its merger with Piedmont Lithium, creating a new lithium entity with equal ownership and a refreshed board. The combined company, soon to be renamed Elevra Lithium, aims to strengthen its position in the global energy transition.

RooLife Group Ltd reported a sharp 51% revenue decline to $4.62 million and a 31% increase in net loss to $2.76 million for FY2025, as it pivots towards higher-margin sectors including renewable energy and global social commerce.

Nanoveu Limited’s transformative half-year report highlights its EMASS acquisition, executive hires, and technology advances amid a $3 million loss and new US OTCQB listing.

Argent BioPharma reported a net loss of A$17.84 million for FY2025, reflecting a strategic pivot towards core drug development and clinical advancement. The company secured key EU approvals and raised significant capital to support its neuro-immune modulatory pipeline.

Wellnex Life Limited reported a strong 40% revenue increase in FY25 driven by its Pain Away brand, yet posted a wider loss due to one-off costs and finance expenses. The company’s balance sheet strengthened following a dual AIM listing and debt settlements.

Chimeric Therapeutics reported a reduced net loss of $10.43 million for FY2025, driven by cost efficiencies and strategic project reprioritisation, while making significant clinical progress in its CAR T-cell and NK cell therapy programs.

Codeifai Limited reported a near doubling of its half-year loss to $3.93 million, alongside a 32% revenue drop, while pursuing transformative AI and quantum security acquisitions and securing $2.35 million in fresh capital.

Dataworks Group Limited reported a modest revenue increase and a reduced net loss for FY25, underpinned by major contract wins in Canada and Australia. The company is targeting cashflow positivity in the first half of FY26 following operational efficiencies and capital raises.

Althea Group Holdings reports a significant reduction in losses for FY25, driven by asset sales and strategic refocus on North American THC beverages. The company completed a $4 million capital raise and navigated leadership changes amid subsidiary liquidations.

Cardiex Limited’s FY2025 results reveal a sharp 67% revenue decline driven by the prior year’s one-off clinical trial payment, while net losses nearly doubled despite ongoing cost reduction efforts and significant capital raises.

Assetora Limited reported a reduced loss of $3.35 million for FY2025 despite an 18% revenue decline, focusing on capital raising and fund growth to stabilize operations.

Adherium Limited reported a $12.68 million net loss for FY2025 as it pivots towards commercialising its smart inhaler technology in the US, supported by a $4.49 million capital raise.